Advertisement
Special Article| Volume 121, 109998, May 2023

Download started.

Ok

Medication abortion with misoprostol-only: A sample protocol

      Keywords

      1. Introduction

      Mifepristone approval by the United States (U.S.) Food and Drug Administration in 2000 revolutionized abortion care in this country. In 2020, 53% of people having facility-based abortions in the U.S. had medication abortions with mifepristone and misoprostol rather than uterine evacuation procedures [
      • Jones R.K.
      • Kirstein M.
      • Philbin J.
      Abortion incidence and service availability in the United States, 2020.
      ]. A key advantage of medication abortion is that it can be provided entirely remotely by telemedicine and mail, which has been critical for patients who face barriers to accessing in-person services [
      • Fok W.K.
      • Mark A.
      Abortion through telemedicine.
      ].
      In the aftermath of the U.S. Supreme Court’s decision in Dobbs v. Jackson Women’s Health Organization which eliminated federal constitutional protections for abortion, the accessibility and availability of mifepristone are under increasing threat. Medication abortion regimens that do not include mifepristone are therefore of urgent interest. The most studied such regimens use misoprostol either alone or in conjunction with methotrexate or letrozole [
      • Zhang J.
      • Zhou K.
      • Shan D.
      • Luo X.
      Medical methods for first trimester abortion.
      ]. Although randomized trials demonstrate that misoprostol-only regimens are somewhat less effective than those that include both mifepristone and misoprostol [
      • Blum J.
      • Raghavan S.
      • Dabash R.
      • Ngoc N.
      • Chelli H.
      • Hajri S.
      • et al.
      Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam.
      ,
      • Jain J.K.
      • Dutton C.
      • Harwood B.
      • Meckstroth K.R.
      • Mishell D.R.
      A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy.
      ,
      • Ngoc N.T.
      • Blum J.
      • Raghavan S.
      • Nga N.T.
      • Dabash R.
      • Diop A.
      • et al.
      Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone.
      ,
      • Dahiya K.
      • Ahuja K.
      • Dhingra A.
      • Duhan N.
      • Nanda S.
      Efficacy and safety of mifepristone and buccal misoprostol versus buccal misoprostol alone for medical abortion.
      ], they cause abortion in the large majority of users. Neither methotrexate-misoprostol [
      • Wiebe E.
      • Dunn S.
      • Guilbert E.
      • Jacot F.
      • Lugtig L.
      Comparison of abortions induced by methotrexate or mifepristone followed by misoprostol.
      ,
      • Creinin M.D.
      • Vittinghoff E.
      • Keder L.
      • Darney P.D.
      • Tiller G.
      Methotrexate and misoprostol for early abortion: a multicenter trial. I. Safety and efficacy.
      ,
      • Borgatta L.
      • Burnhill M.S.
      • Tyson J.
      • Leonhardt K.K.
      • Hausknecht R.U.
      • Haskell S.
      Early medical abortion with methotrexate and misoprostol.
      ,
      • Creinin M.D.
      • Potter C.
      • Holovanisin M.
      • Janczukiewicz L.
      • Pymar H.C.
      • Schwartz J.L.
      • et al.
      Mifepristone and misoprostol and methotrexate/misoprostol in clinical practice for abortion.
      ] nor letrozole-misoprostol [
      • Lee V.C.Y.
      • Tang O.S.
      • Ng E.H.Y.
      • Yeung W.S.B.
      • Ho P.C.
      A pilot study on the use of letrozole with either misoprostol or mifepristone for termination of pregnancy up to 63 days.
      ,
      • Lee V.C.Y.
      • Ng E.H.Y.
      • Yeung W.S.B.
      • Ho P.C.
      Misoprostol with or without letrozole pretreatment for termination of pregnancy: a randomized controlled trial.
      ,
      • Yeung T.W.Y.
      • Lee V.C.Y.
      • Ng E.H.Y.
      • Ho P.C.
      A pilot study on the use of a 7-day course of letrozole followed by misoprostol for the termination of early pregnancy up to 63 days.
      ,
      • Shochet T.
      • Turok D.
      • Frye L.J.
      • Sexsmith C.D.
      • Gawron L.M.
      • Kaiser J.E.
      • et al.
      Single dose letrozole and misoprostol for termination of pregnancy through 63 days’ gestation: a pilot study.
      ] regimens have demonstrated advantages in effectiveness, ease of use, or time to abortion over multi-dose misoprostol-only regimens.
      In settings where mifepristone is not available, and especially outside the U.S., clinicians and people who self-manage abortion have been using misoprostol-only for decades [
      • Jayaweera R.T.
      • Moseson H.
      • Gerdts C.
      Misoprostol in the era of COVID-19: a love letter to the original medical abortion pill.
      ]. Misoprostol-only regimens are endorsed as a medically acceptable option by the World Health Organization [
      World Health Organization
      ] and other international and national professional guidelines for abortion care [
      • Costescu D.
      • Guilbert E.
      • Bernardin J.
      • Black A.
      • Dunn S.
      • Fitzsimmons B.
      • et al.
      Medical abortion.
      ,
      National Abortion Federation
      ,

      Royal College of Obstetricians and Gynaecologists. Best practice in abortion care. London, England; 2022. https://www.rcog.org.uk/media/geify5bx/abortion-care-best-practice-paper-april-2022.pdf.

      ]. However, documented experience in the U.S. has been limited. Here, we present a brief summary of data on misoprostol-only abortion and a sample protocol for U.S. clinicians who wish to offer it.

      2. Data on effectiveness and safety of misoprostol-only regimens

      A systematic review published in 2019 [
      • Raymond E.G.
      • Harrison M.S.
      • Weaver M.A.
      Efficacy of misoprostol alone for first-trimester medical abortion: a systematic review.
      ] summarized 38 studies of the effectiveness and safety of a large variety of misoprostol-only regimens for medication abortion in the first trimester. Of the 12,829 patients who provided outcome data, 78% aborted completely without a procedure or unplanned additional medications, a substantially lower proportion than the approximately 95% expected after the use of mifepristone and misoprostol at ≤10 weeks of gestation [
      • Chen M.J.
      • Creinin M.D.
      Mifepristone with buccal misoprostol for medical abortion: a systematic review.
      ,
      • Raymond E.G.
      • Shannon C.
      • Weaver M.A.
      • Winikoff B.
      First-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic review.
      ]. Several features of misoprostol-only regimens were associated with higher effectiveness, including the number of misoprostol doses, the amount of misoprostol per dose, and administration by a sublingual, vaginal or buccal route (as opposed to orally). The overall data suggested that if vaginal administration is chosen, moistening the misoprostol tablets before insertion may improve effectiveness. One randomized trial reported higher effectiveness after sublingual than buccal administration [
      • Sheldon W.R.
      • Durocher J.
      • Dzuba I.G.
      • Sayette H.
      • Martin R.
      • Velasco M.C.
      • et al.
      Early abortion with buccal versus sublingual misoprostol alone: a multicenter, randomized trial.
      ].
      The systematic review examined effectiveness among subgroups of patients who received regimens with characteristics associated with higher effectiveness. In the 20 studies in which patients received at least 3 or more doses of misoprostol, the first of which contained 800 µg administered sublingually, vaginally (moistened), or buccally, 87% of the 5338 evaluable patients aborted completely without additional treatment [
      • Raymond E.G.
      • Harrison M.S.
      • Weaver M.A.
      Efficacy of misoprostol alone for first-trimester medical abortion: a systematic review.
      ]. In three of those studies [
      • Carbonell J.L.L.
      • Rodríguez J.
      • Velazco A.
      • Tanda R.
      • Sánchez C.
      • Barambio S.
      • et al.
      Oral and vaginal misoprostol 800 microg every 8h for early abortion.
      ,
      • Singh K.
      • Fong Y.F.
      • Dong F.
      A viable alternative to surgical vacuum aspiration: repeated doses of intravaginal misoprostol over 9 h for medical termination of pregnancies up to eight weeks.
      ,
      • Tebbets C.
      • Santana D.
      • Ros Silvestre J.
      • Redwine D.
      Building bridges: a case for community health worker provision of misoprostol-only abortion in the first trimester.
      ], patients took up to four or six doses and had routine clinical follow-up; of the 775 patients in those studies plus 388 patients meeting those criteria in an additional study published since the review [
      • Sheldon W.R.
      • Durocher J.
      • Dzuba I.G.
      • Sayette H.
      • Martin R.
      • Velasco M.C.
      • et al.
      Early abortion with buccal versus sublingual misoprostol alone: a multicenter, randomized trial.
      ], the planned treatment was successful in 93%.
      Ongoing pregnancy is more likely after the misoprostol-only regimen than after mifepristone and misoprostol. Of all 6359 patients in the 2019 review who were evaluated for ongoing pregnancy after misoprostol-only treatment, 6% had confirmed viable pregnancies at some point during follow-up [
      • Raymond E.G.
      • Harrison M.S.
      • Weaver M.A.
      Efficacy of misoprostol alone for first-trimester medical abortion: a systematic review.
      ]. This proportion was 3% among patients who took up to 4 to 6 misoprostol doses as described above. Ongoing pregnancies comprised 39% of total treatment failures in the total 6359 patients and 40% in the group who took up to 4 to 6 doses. In contrast, the expected ongoing pregnancy rate after the use of mifepristone and misoprostol through 9 weeks of gestation is about 1% to 2% and about 25% of total treatment failures are ongoing pregnancies [
      • Raymond E.G.
      • Shannon C.
      • Weaver M.A.
      • Winikoff B.
      First-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic review.
      ].
      Some studies reported that the effectiveness of the misoprostol-only treatment declined with gestational duration within the first trimester [
      • Ngoc N.T.
      • Blum J.
      • Raghavan S.
      • Nga N.T.
      • Dabash R.
      • Diop A.
      • et al.
      Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone.
      ,
      • Borgatta L.
      • Mullally B.
      • Vragovic O.
      • Gittinger E.
      • Chen A.
      Misoprostol as the primary agent for medical abortion in a low-income urban setting.
      ,
      • von Hertzen H.
      • Piaggio G.
      • Huong N.T.M.
      • Arustamyan K.
      • Cabezas E.
      • Gomez M.
      • et al.
      Efficacy of two intervals and two routes of administration of misoprostol for termination of early pregnancy: a randomised controlled equivalence trial.
      ,
      • Zikopoulos K.A.
      • Papanikolaou E.G.
      • Kalantaridou S.N.
      • Tsanadis G.D.
      • Plachouras N.I.
      • Dalkalitsis N.A.
      • et al.
      Early pregnancy termination with vaginal misoprostol before and after 42 days gestation.
      ], whereas others did not observe this trend [
      • Sheldon W.R.
      • Durocher J.
      • Dzuba I.G.
      • Sayette H.
      • Martin R.
      • Velasco M.C.
      • et al.
      Early abortion with buccal versus sublingual misoprostol alone: a multicenter, randomized trial.
      ,
      • Carbonell J.L.L.
      • Rodríguez J.
      • Velazco A.
      • Tanda R.
      • Sánchez C.
      • Barambio S.
      • et al.
      Oral and vaginal misoprostol 800 microg every 8h for early abortion.
      ,
      • Singh K.
      • Fong Y.F.
      • Dong F.
      A viable alternative to surgical vacuum aspiration: repeated doses of intravaginal misoprostol over 9 h for medical termination of pregnancies up to eight weeks.
      ,
      • Tebbets C.
      • Santana D.
      • Ros Silvestre J.
      • Redwine D.
      Building bridges: a case for community health worker provision of misoprostol-only abortion in the first trimester.
      ]. Data on misoprostol-only abortions at 10 to 12 weeks of gestation are limited [
      • Raymond E.G.
      • Harrison M.S.
      • Weaver M.A.
      Efficacy of misoprostol alone for first-trimester medical abortion: a systematic review.
      ]. No information is available on the use of misoprostol-only when the gestation is so early that the pregnancy cannot be seen on ultrasound. However, some studies have suggested that treatment with mifepristone and misoprostol is less effective in such very early pregnancies than later in gestation [
      • Bizjak I.
      • Fiala C.
      • Berggren L.
      • Hognert H.
      • Saav I.
      • Bring J.
      • et al.
      Efficacy and safety of very early medical termination of pregnancy: a cohort study.
      ,
      • Goldstone P.
      • Michelson J.
      • Williamson E.
      Effectiveness of early medical abortion using low-dose mifepristone and buccal misoprostol in women with no defined intrauterine gestational sac.
      ,
      • Schaff E.A.
      • Fielding S.L.
      • Eisinger S.
      • Stadalius L.
      Mifepristone and misoprostol for early abortion when no gestational sac is present.
      ,
      • Goldberg A.B.
      • Fulcher I.R.
      • Fortin J.
      • Hofer R.K.
      • Cottrill A.
      • Dethier D.
      • et al.
      Mifepristone and misoprostol for undesired pregnancy of unknown location.
      ], and it is possible that the same is true of misoprostol-only regimens.
      Several recent studies evaluated the effectiveness of misoprostol-only regimens for self-managed abortion outside the U.S. These studies reported very high success; the combined proportion in three such studies was 98% [
      • Foster A.M.
      • Arnott G.
      • Hobstetter M.
      Community-based distribution of misoprostol for early abortion: evaluation of a program along the Thailand-Burma border.
      ,
      • Foster A.M.
      • Messier K.
      • Aslam M.
      • Shabir N.
      Community-based distribution of misoprostol for early abortion: outcomes from a program in Sindh, Pakistan.
      ,
      • Moseson H.
      • Jayaweera R.
      • Egwuatu I.
      • Grosso B.
      • Kristianingrum I.A.
      • Nmezi S.
      • et al.
      Effectiveness of self-managed medication abortion with accompaniment support in Argentina and Nigeria (SAFE): a prospective, observational cohort study and non-inferiority analysis with historical controls.
      ]. Abortion practice in these settings differed from U.S. practice; most notably, outcome ascertainment relied solely on patient report 3 to 4 weeks after treatment, and procedural intervention was not readily accessible. Thus, US clinicians using this protocol and their patients are unlikely to observe such high effectiveness. Nevertheless, the results of these studies lend insight into experience with and the acceptability of misoprostol-only regimens, particularly in less medicalized settings.
      Misoprostol-only treatments are very safe: across all studies in the 2019 review, at most 0.7% of patients were hospitalized or received a transfusion. Bleeding after misoprostol-only typically lasts about 2 weeks [
      • Jain J.K.
      • Dutton C.
      • Harwood B.
      • Meckstroth K.R.
      • Mishell D.R.
      A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy.
      ,
      • Fekih M.
      • Fathallah K.
      • Ben Regaya L.
      • Bouguizane S.
      • Chaieb A.
      • Bibi M.
      • et al.
      Sublingual misoprostol for first trimester termination of pregnancy.
      ,
      • Chawdhary R.
      • Rana A.
      • Pradhan N.
      Mifepristone plus vaginal misoprostol vs vaginal misoprostol alone for medical abortion in gestation 63 days or less in Nepalese women: a quasi-randomized controlled trial.
      ]. Some data from studies directly comparing misoprostol-only regimens to those containing mifepristone suggest that the former may result in a higher incidence of side effects, particularly diarrhea, fever, and chills [
      • Blum J.
      • Raghavan S.
      • Dabash R.
      • Ngoc N.
      • Chelli H.
      • Hajri S.
      • et al.
      Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam.
      ,
      • Ngoc N.T.
      • Blum J.
      • Raghavan S.
      • Nga N.T.
      • Dabash R.
      • Diop A.
      • et al.
      Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone.
      ,
      • Chawdhary R.
      • Rana A.
      • Pradhan N.
      Mifepristone plus vaginal misoprostol vs vaginal misoprostol alone for medical abortion in gestation 63 days or less in Nepalese women: a quasi-randomized controlled trial.
      ,
      • Jain J.K.
      • Meckstroth K.R.
      • Park M.
      • Mishell D.R.
      A comparison of tamoxifen and misoprostol to misoprostol alone for early pregnancy termination.
      ]. Two randomized trials suggested that sublingual use may result in more side effects than buccal [
      • Sheldon W.R.
      • Durocher J.
      • Dzuba I.G.
      • Sayette H.
      • Martin R.
      • Velasco M.C.
      • et al.
      Early abortion with buccal versus sublingual misoprostol alone: a multicenter, randomized trial.
      ] or vaginal [
      • von Hertzen H.
      • Piaggio G.
      • Huong N.T.M.
      • Arustamyan K.
      • Cabezas E.
      • Gomez M.
      • et al.
      Efficacy of two intervals and two routes of administration of misoprostol for termination of early pregnancy: a randomised controlled equivalence trial.
      ] use.
      In the 2019 review, 2961 patients provided data on satisfaction, of whom 78% were satisfied or very satisfied, and 76% said that they would use the method again if needed.

      3. Sample protocol

      The sample protocol (Fig. 1) is intended as a guidance to assist facility-based providers who are familiar with mifepristone and misoprostol use in early pregnancy. Providers should use judgment to adapt the protocol for their practice settings and patient populations. Below are some comments on various provisions of this protocol.
      Fig. 1
      Fig. 1Sample protocol for provision of medication abortion with misoprostol-only.

      3.1 Patient selection

      The sample protocol specifies a gestational limit of 12 weeks, consistent with the 2022 World Health Organization guideline [
      World Health Organization
      ]. Otherwise, eligibility criteria are the same as those commonly accepted for medication abortion with mifepristone and misoprostol, except that criteria that apply solely to mifepristone are omitted. Specifically, people who have chronic adrenal failure, inherited porphyria, or allergy to mifepristone, and those who are taking long-term systemic corticosteroids, need not be excluded from receiving misoprostol-only. Pregnancy should be confirmed by urine pregnancy test or ultrasound, and gestational duration assessed by menstrual or other history, examination, or ultrasound [
      • Raymond E.G.
      • Grossman D.
      • Mark A.
      • Upadhyay U.D.
      • Dean G.
      • Creinin M.D.
      • et al.
      Commentary: No-test medication abortion: a sample protocol for increasing access during a pandemic and beyond.
      ,
      • Upadhyay U.D.
      • Raymond E.G.
      • Koenig L.R.
      • Coplon L.
      • Gold M.
      • Kaneshiro B.
      • et al.
      Outcomes and safety of history-based screening for medication abortion: a retrospective multicenter cohort study.
      ]. Clinicians may choose to consider patient reports of results of these tests as acceptable. Patients with ultrasound-diagnosed pregnancy of unknown location and without signs or symptoms of ectopic pregnancy should be treated according to standard protocols for such cases [
      National Abortion Federation
      ].

      3.2 Rh typing and other pretreatment laboratory testing

      Rh testing and provision of Rh immune globulin are unnecessary prior to medication abortion before 12 weeks of gestation [
      • Mark A.
      • Foster A.M.
      • Grossman D.
      • Prager S.W.
      • Reeves M.
      • Velasquez C.V.
      • et al.
      Foregoing Rh testing and anti-D immunoglobulin for women presenting for early abortion: a recommendation from the National Abortion Federation’s Clinical Policies Committee.
      ,
      • Horvath S.
      • Tsao P.
      • Huang Z.Y.
      • Zhao L.
      • Du Y.
      • Sammel M.D.
      • et al.
      The concentration of fetal red blood cells in first-trimester pregnant women undergoing uterine aspiration is below the calculated threshold for Rh sensitization.
      ], and some recent U.S. [
      • Horvath S.
      • Goyal V.
      • Traxler S.
      • Prager S.
      Society of Family Planning committee consensus on Rh testing in early pregnancy.
      ] and international guidelines [
      World Health Organization
      ,

      Royal College of Obstetricians and Gynaecologists. Best practice in abortion care. London, England; 2022. https://www.rcog.org.uk/media/geify5bx/abortion-care-best-practice-paper-april-2022.pdf.

      ] have been updated to reflect this. Hemoglobin or hematocrit testing is not needed if the patient has no history or symptoms of anemia. If follow-up with serial serum human chorionic gonadotropin (HCG) tests is planned, the patient should provide a serum sample on the day of treatment initiation as a baseline.

      3.3 Treatment regimen

      The treatment regimen in the sample protocol is flexible, recognizing the many different circumstances in which misoprostol-only may be provided, including in person and via telehealth, as well as variations in patients’ ability to obtain additional misoprostol or other abortion treatments if needed after the initial prescription. Thus, the protocol specifies that each patient should receive three or four doses of misoprostol 800 µg at the clinician’s discretion, plus an additional dose for use in case of need. The patient should be instructed to take the initial three or four doses at 3 hours intervals regardless of bleeding or other symptoms that occur during use. If the patient has had no more than scant bleeding within 3 hours after the last dose or is not sure that the pregnancy has passed, the patient should take the extra dose.
      The protocol recommends that the patient should self-administer the doses sublingually or vaginally, according to patient preference at the time of each dose. Patients should not simply swallow the pills. Although sublingual administration may cause more side effects, it also may be more practical, especially if the patient is bleeding. Vaginal administration may be more comfortable than sublingual dosing if the patient is nauseated. If the patient chooses that route, moistening the tablets with a few drops of water before administration may enhance effectiveness. Moistening may be logistically difficult for patients, however. Patients should be informed that remnants of the tablets may be visible in the vagina days after insertion.
      The protocol recommends providing the patient with at least one urine pregnancy test, even if a different follow-up test is planned, in order to enable self-assessment if the patient does not obtain the planned test.

      3.4 Symptom management

      Misoprostol causes uterine cramping, nausea, and vomiting, and some research studies report a higher incidence of fever, chills, and diarrhea [
      • Blum J.
      • Raghavan S.
      • Dabash R.
      • Ngoc N.
      • Chelli H.
      • Hajri S.
      • et al.
      Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam.
      ,
      • Ngoc N.T.
      • Blum J.
      • Raghavan S.
      • Nga N.T.
      • Dabash R.
      • Diop A.
      • et al.
      Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone.
      ,
      • Chawdhary R.
      • Rana A.
      • Pradhan N.
      Mifepristone plus vaginal misoprostol vs vaginal misoprostol alone for medical abortion in gestation 63 days or less in Nepalese women: a quasi-randomized controlled trial.
      ,
      • Jain J.K.
      • Meckstroth K.R.
      • Park M.
      • Mishell D.R.
      A comparison of tamoxifen and misoprostol to misoprostol alone for early pregnancy termination.
      ] after misoprostol-only regimens than after mifepristone and misoprostol. Thus, the sample protocol specifies that clinicians should provide or recommend antipyretics, analgesics, antiemetics, and antidiarrheal medication. Studies of patients treated with mifepristone and misoprostol have indicated that for pain relief, ibuprofen was superior to acetaminophen [
      • Livshits A.
      • Machtinger R.
      • David L.B.
      • Spira M.
      • Moshe-Zahav A.
      • Seidman D.S.
      Ibuprofen and paracetamol for pain relief during medical abortion: a double-blind randomized controlled study.
      ] and that transcutaneous electrical nerve stimulation [
      • Goldman A.R.
      • Porsch L.
      • Hintermeister A.
      • Dragoman M.
      Transcutaneous electrical nerve stimulation to reduce pain with medication abortion: a randomized controlled trial.
      ] and prophylactic use of ibuprofen combined with metoclopramide [
      • Dragoman M.V.
      • Grossman D.
      • Nguyen M.H.
      • Habib N.
      • Kapp N.
      • Tamang A.
      • et al.
      Two prophylactic pain management regimens for medical abortion ≤63 days’ gestation with mifepristone and misoprostol: a multicenter, randomized, placebo-controlled trial.
      ] may be useful. One comparative study found that loperamide reduced diarrhea [
      • Jain J.K.
      • Harwood B.
      • Meckstroth K.R.
      • Mishell D.R.
      Early pregnancy termination with vaginal misoprostol combined with loperamide and acetaminophen prophylaxis.
      ].

      3.5 Follow-up

      Limited data are available on the expected timing or duration of patient symptoms after successful abortion with misoprostol-only. The expected rate of decline of HCG levels in urine or serum is also unknown. The sample protocol assumes that both symptoms and laboratory markers of successful abortion will occur similarly after use of misoprostol with or without mifepristone. The recommended follow-up approach in the sample protocol is therefore consistent with commonly used clinical approaches used after treatment with mifepristone and misoprostol.
      Specifically, each patient should have a follow-up plan, which may include a self-administered symptom checklist with instructions on when to contact the provider or a scheduled in-person or telemedicine encounter 1 week after treatment to assess symptoms. Abortion completeness should be confirmed with a test: either a high-sensitivity urine pregnancy test performed at home 4–5 weeks after treatment or an ultrasound, pelvic examination, or serum serial HCG tests. The results of these evaluations should be interpreted and managed according to standards for the assessment of patients using mifepristone and misoprostol.
      However, clinicians should be aware that if HCG levels decline more slowly after treatment with misoprostol-only, then documenting complete abortion using urine pregnancy tests or serial serum HCGs may take longer than would be expected after abortion with mifepristone and misoprostol. Although a slow decline is not likely to increase the risk of missing a treatment failure or ectopic pregnancy, it may mean that patients using misoprostol-only may require more post-treatment contacts and evaluations to confirm treatment success than is typical after the use of regimens containing mifepristone. Nevertheless, because of the higher risk of ongoing pregnancy after treatment with misoprostol-only, all post-treatment symptoms or signs that the pregnancy may be continuing, including a positive urine pregnancy test 4 weeks after treatment, should be further evaluated.

      3.6 Management of treatment failures

      Ongoing pregnancy or incomplete abortion after the use of misoprostol-only may be managed with a uterine evacuation procedure, a standard regimen of mifepristone and misoprostol if available, or additional misoprostol doses. No data are available that establish the effectiveness of continued misoprostol dosing to terminate a viable pregnancy that has already been exposed to three or more prior doses. Thus, if ongoing pregnancy has been definitively diagnosed, the first two of these alternatives are preferred, although additional misoprostol also may be useful if the patient will not be able to immediately obtain other treatments. If the pregnancy is no longer viable or if the viability of the pregnancy is unknown, and the patient does not have heavy bleeding or other acute symptoms mandating immediate treatment, additional misoprostol is a reasonable primary option. Data indicate that treatment success may increase with the amount of time between treatment and the decision to intervene [
      • Raymond E.G.
      • Harrison M.S.
      • Weaver M.A.
      Efficacy of misoprostol alone for first-trimester medical abortion: a systematic review.
      ], suggesting that when clinically appropriate, conservative management can be beneficial.

      4. Patient education

      Patients should be reassured that misoprostol-only is a well-studied and recommended regimen for abortion.
      Every patient contemplating medication abortion with misoprostol-only should receive sufficient education to understand the risks, benefits, and alternatives to the regimen, including uterine evacuation and treatment with mifepristone and misoprostol if available, to enable an informed choice. Counseling should be tailored to each patient’s individual situation. Patients using misoprostol-only may experience more immediate, intense, and prolonged side effects than those using a mifepristone regimen. The risk of treatment failure requiring additional medications or a procedure (about 10%) is higher after misoprostol-only than after regimens containing mifepristone. About 3% to 6% of patients using misoprostol-only may have an ongoing pregnancy. Patients should be informed that misoprostol can be teratogenic if the pregnancy is not terminated; prospective studies have suggested that exposure in early pregnancy may double the risk of cranial nerve anomalies, limb defects, and other major birth defects [
      • Auffret M.
      • Bernard-Phalippon N.
      • Dekemp J.
      • Carlier P.
      • Gervoise Boyer M.
      • Vial T.
      • et al.
      Misoprostol exposure during the first trimester of pregnancy: Is the malformation risk varying depending on the indication.
      ,
      • Vauzelle C.
      • Beghin D.
      • Cournot M.-P.
      • Elefant E.
      Birth defects after exposure to misoprostol in the first trimester of pregnancy: prospective follow-up study.
      ]. However, for patients who cannot readily obtain or prefer not to use mifepristone, a misoprostol-only regimen is a reasonable option.
      To minimize risk and identify treatment failures promptly, patients should take all doses of misoprostol recommended by the abortion provider. The patient should be attentive to signs of possible treatment failure or complications and should have or perform the planned follow-up test. If the patient is unable to complete the prescribed regimen or to obtain or perform the follow-up test, the patient should contact the provider.
      A sample instruction sheet for patients is provided in Figure 2.
      Fig. 2
      Fig. 2Sample instructions for patients receiving medication abortion with misoprostol-only.

      5. Conclusion

      After more than 22 years on the U.S. market and clinical use for more than 3 decades throughout the world, the safety and effectiveness of mifepristone are conclusively established. From a medical perspective, to prohibit the use of this drug for abortion care is senseless. However, even if legally available, mifepristone may not be accessible to some patients due to cost, telehealth regulations, distribution restrictions, contraindications, or personal reasons. Offering medication abortion with misoprostol-only is a safe, effective, patient-centered approach to enable continued access to this essential health service.

      Acknowledgment

      The Society of Family Planning endorses this protocol.

      References

        • Jones R.K.
        • Kirstein M.
        • Philbin J.
        Abortion incidence and service availability in the United States, 2020.
        Perspect Sex Reprod Health. 2022; 54: 128-141https://doi.org/10.1363/psrh.12215
        • Fok W.K.
        • Mark A.
        Abortion through telemedicine.
        Curr Opin Obstet Gynecol. 2018; 30: 394-399https://doi.org/10.1097/GCO.0000000000000498
        • Zhang J.
        • Zhou K.
        • Shan D.
        • Luo X.
        Medical methods for first trimester abortion.
        Cochrane Database Syst Rev. 2022; 5CD002855https://doi.org/10.1002/14651858.CD002855.pub5
        • Blum J.
        • Raghavan S.
        • Dabash R.
        • Ngoc N.
        • Chelli H.
        • Hajri S.
        • et al.
        Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam.
        Int J Gynaecol Obstet. 2012; 118 (https://doi.org/10.1016/j.ijgo.2012.03.039 S0020-7292(12)00215-9 [pii]): 166-171
        • Jain J.K.
        • Dutton C.
        • Harwood B.
        • Meckstroth K.R.
        • Mishell D.R.
        A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy.
        Hum Reprod. 2002; 17: 1477-1482
        • Ngoc N.T.
        • Blum J.
        • Raghavan S.
        • Nga N.T.
        • Dabash R.
        • Diop A.
        • et al.
        Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone.
        Contraception. 2011; 83 (https://doi.org/S0010-7824(10)00522-6 [pii]): 410-417https://doi.org/10.1016/j.contraception.2010.09.002
        • Dahiya K.
        • Ahuja K.
        • Dhingra A.
        • Duhan N.
        • Nanda S.
        Efficacy and safety of mifepristone and buccal misoprostol versus buccal misoprostol alone for medical abortion.
        Arch Gynecol Obstet. 2012; 285: 1055-1058https://doi.org/10.1007/s00404-011-2110-8
        • Wiebe E.
        • Dunn S.
        • Guilbert E.
        • Jacot F.
        • Lugtig L.
        Comparison of abortions induced by methotrexate or mifepristone followed by misoprostol.
        Obstet Gynecol. 2002; 99: 813-819https://doi.org/10.1016/s0029-7844(02)01944-0
        • Creinin M.D.
        • Vittinghoff E.
        • Keder L.
        • Darney P.D.
        • Tiller G.
        Methotrexate and misoprostol for early abortion: a multicenter trial. I. Safety and efficacy.
        Contraception. 1996; 53 (https://doi.org/0010782496000807 [pii]): 321-327
        • Borgatta L.
        • Burnhill M.S.
        • Tyson J.
        • Leonhardt K.K.
        • Hausknecht R.U.
        • Haskell S.
        Early medical abortion with methotrexate and misoprostol.
        Obstet Gynecol. 2001; 97 (https://doi.org/S0029-7844(00)01090-5 [pii]): 11-16
        • Creinin M.D.
        • Potter C.
        • Holovanisin M.
        • Janczukiewicz L.
        • Pymar H.C.
        • Schwartz J.L.
        • et al.
        Mifepristone and misoprostol and methotrexate/misoprostol in clinical practice for abortion.
        Am J Obstet Gynecol. 2003; 188 (https://doi.org/S0002937802714610 [pii]): 664-669
        • Lee V.C.Y.
        • Tang O.S.
        • Ng E.H.Y.
        • Yeung W.S.B.
        • Ho P.C.
        A pilot study on the use of letrozole with either misoprostol or mifepristone for termination of pregnancy up to 63 days.
        Contraception. 2011; 83: 62-67https://doi.org/10.1016/j.contraception.2010.05.014
        • Lee V.C.Y.
        • Ng E.H.Y.
        • Yeung W.S.B.
        • Ho P.C.
        Misoprostol with or without letrozole pretreatment for termination of pregnancy: a randomized controlled trial.
        Obstet Gynecol. 2011; 117: 317-323https://doi.org/10.1097/AOG.0b013e3182073fbf
        • Yeung T.W.Y.
        • Lee V.C.Y.
        • Ng E.H.Y.
        • Ho P.C.
        A pilot study on the use of a 7-day course of letrozole followed by misoprostol for the termination of early pregnancy up to 63 days.
        Contraception. 2012; 86: 763-769https://doi.org/10.1016/j.contraception.2012.05.009
        • Shochet T.
        • Turok D.
        • Frye L.J.
        • Sexsmith C.D.
        • Gawron L.M.
        • Kaiser J.E.
        • et al.
        Single dose letrozole and misoprostol for termination of pregnancy through 63 days’ gestation: a pilot study.
        Contraception. 2022; 109924https://doi.org/10.1016/j.contraception.2022.109924
        • Jayaweera R.T.
        • Moseson H.
        • Gerdts C.
        Misoprostol in the era of COVID-19: a love letter to the original medical abortion pill.
        Sex Reprod Health Matters. 2020; 281829406https://doi.org/10.1080/26410397.2020.1829406
        • World Health Organization
        Abortion care guideline. World Health Organization, Geneva, Switzerland2022
        • Costescu D.
        • Guilbert E.
        • Bernardin J.
        • Black A.
        • Dunn S.
        • Fitzsimmons B.
        • et al.
        Medical abortion.
        J Obstet Gynaecol Can. 2016; 38: 366-389https://doi.org/10.1016/j.jogc.2016.01.002
        • National Abortion Federation
        Clinical policy guidelines. National Abortion Federation, Washington, DC2022
      1. Royal College of Obstetricians and Gynaecologists. Best practice in abortion care. London, England; 2022. https://www.rcog.org.uk/media/geify5bx/abortion-care-best-practice-paper-april-2022.pdf.

        • Raymond E.G.
        • Harrison M.S.
        • Weaver M.A.
        Efficacy of misoprostol alone for first-trimester medical abortion: a systematic review.
        Obstet Gynecol. 2019; 133: 137-147https://doi.org/10.1097/AOG.0000000000003017
        • Chen M.J.
        • Creinin M.D.
        Mifepristone with buccal misoprostol for medical abortion: a systematic review.
        Obstet Gynecol. 2015; 126: 12-21https://doi.org/10.1097/AOG.0000000000000897
        • Raymond E.G.
        • Shannon C.
        • Weaver M.A.
        • Winikoff B.
        First-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic review.
        Contraception. 2013; 87: 26-37https://doi.org/10.1016/j.contraception.2012.06.011
        • Sheldon W.R.
        • Durocher J.
        • Dzuba I.G.
        • Sayette H.
        • Martin R.
        • Velasco M.C.
        • et al.
        Early abortion with buccal versus sublingual misoprostol alone: a multicenter, randomized trial.
        Contraception. 2019; 99: 272-277https://doi.org/10.1016/j.contraception.2019.02.002
        • Carbonell J.L.L.
        • Rodríguez J.
        • Velazco A.
        • Tanda R.
        • Sánchez C.
        • Barambio S.
        • et al.
        Oral and vaginal misoprostol 800 microg every 8h for early abortion.
        Contraception. 2003; 67: 457-462https://doi.org/10.1016/s0010-7824(03)00043-x
        • Singh K.
        • Fong Y.F.
        • Dong F.
        A viable alternative to surgical vacuum aspiration: repeated doses of intravaginal misoprostol over 9 h for medical termination of pregnancies up to eight weeks.
        BJOG. 2003; 110: 175-180
        • Tebbets C.
        • Santana D.
        • Ros Silvestre J.
        • Redwine D.
        Building bridges: a case for community health worker provision of misoprostol-only abortion in the first trimester.
        J Womens Health. 2018; 27: 311-316https://doi.org/10.1089/jwh.2016.6144
        • Borgatta L.
        • Mullally B.
        • Vragovic O.
        • Gittinger E.
        • Chen A.
        Misoprostol as the primary agent for medical abortion in a low-income urban setting.
        Contraception. 2004; 70: 121-126https://doi.org/10.1016/j.contraception.2004.03.007
        • von Hertzen H.
        • Piaggio G.
        • Huong N.T.M.
        • Arustamyan K.
        • Cabezas E.
        • Gomez M.
        • et al.
        Efficacy of two intervals and two routes of administration of misoprostol for termination of early pregnancy: a randomised controlled equivalence trial.
        Lancet. 2007; 369: 1938-1946https://doi.org/10.1016/S0140-6736(07)60914-3
        • Zikopoulos K.A.
        • Papanikolaou E.G.
        • Kalantaridou S.N.
        • Tsanadis G.D.
        • Plachouras N.I.
        • Dalkalitsis N.A.
        • et al.
        Early pregnancy termination with vaginal misoprostol before and after 42 days gestation.
        Hum Reprod. 2002; 17: 3079-3083https://doi.org/10.1093/humrep/17.12.3079
        • Bizjak I.
        • Fiala C.
        • Berggren L.
        • Hognert H.
        • Saav I.
        • Bring J.
        • et al.
        Efficacy and safety of very early medical termination of pregnancy: a cohort study.
        BJOG. 2017; 124: 1993-1999https://doi.org/10.1111/1471-0528.14904
        • Goldstone P.
        • Michelson J.
        • Williamson E.
        Effectiveness of early medical abortion using low-dose mifepristone and buccal misoprostol in women with no defined intrauterine gestational sac.
        Contraception. 2013; 87: 855-858https://doi.org/10.1016/j.contraception.2012.10.013
        • Schaff E.A.
        • Fielding S.L.
        • Eisinger S.
        • Stadalius L.
        Mifepristone and misoprostol for early abortion when no gestational sac is present.
        Contraception. 2001; 63: 251-254
        • Goldberg A.B.
        • Fulcher I.R.
        • Fortin J.
        • Hofer R.K.
        • Cottrill A.
        • Dethier D.
        • et al.
        Mifepristone and misoprostol for undesired pregnancy of unknown location.
        Obstet Gynecol. 2022; 139: 771-780https://doi.org/10.1097/AOG.0000000000004756
        • Foster A.M.
        • Arnott G.
        • Hobstetter M.
        Community-based distribution of misoprostol for early abortion: evaluation of a program along the Thailand-Burma border.
        Contraception. 2017; 96: 242-247https://doi.org/10.1016/j.contraception.2017.06.006
        • Foster A.M.
        • Messier K.
        • Aslam M.
        • Shabir N.
        Community-based distribution of misoprostol for early abortion: outcomes from a program in Sindh, Pakistan.
        Contraception. 2022; 109: 49-51https://doi.org/10.1016/j.contraception.2022.01.005
        • Moseson H.
        • Jayaweera R.
        • Egwuatu I.
        • Grosso B.
        • Kristianingrum I.A.
        • Nmezi S.
        • et al.
        Effectiveness of self-managed medication abortion with accompaniment support in Argentina and Nigeria (SAFE): a prospective, observational cohort study and non-inferiority analysis with historical controls.
        Lancet Glob Health. 2022; 10: e105-e113https://doi.org/10.1016/S2214-109X(21)00461-7
        • Fekih M.
        • Fathallah K.
        • Ben Regaya L.
        • Bouguizane S.
        • Chaieb A.
        • Bibi M.
        • et al.
        Sublingual misoprostol for first trimester termination of pregnancy.
        Int J Gynaecol Obstet. 2010; 109: 67-70https://doi.org/10.1016/j.ijgo.2009.11.008
        • Chawdhary R.
        • Rana A.
        • Pradhan N.
        Mifepristone plus vaginal misoprostol vs vaginal misoprostol alone for medical abortion in gestation 63 days or less in Nepalese women: a quasi-randomized controlled trial.
        J Obstet Gynaecol Res. 2009; 35: 78-85https://doi.org/10.1111/j.1447-0756.2008.00864.x
        • Jain J.K.
        • Meckstroth K.R.
        • Park M.
        • Mishell D.R.
        A comparison of tamoxifen and misoprostol to misoprostol alone for early pregnancy termination.
        Contraception. 1999; 60: 353-356https://doi.org/10.1016/s0010-7824(99)00105-5
        • Raymond E.G.
        • Grossman D.
        • Mark A.
        • Upadhyay U.D.
        • Dean G.
        • Creinin M.D.
        • et al.
        Commentary: No-test medication abortion: a sample protocol for increasing access during a pandemic and beyond.
        Contraception. 2020; 101: 361-366https://doi.org/10.1016/j.contraception.2020.04.005
        • Upadhyay U.D.
        • Raymond E.G.
        • Koenig L.R.
        • Coplon L.
        • Gold M.
        • Kaneshiro B.
        • et al.
        Outcomes and safety of history-based screening for medication abortion: a retrospective multicenter cohort study.
        JAMA Intern Med. 2022; 182: 482-491https://doi.org/10.1001/jamainternmed.2022.0217
        • Mark A.
        • Foster A.M.
        • Grossman D.
        • Prager S.W.
        • Reeves M.
        • Velasquez C.V.
        • et al.
        Foregoing Rh testing and anti-D immunoglobulin for women presenting for early abortion: a recommendation from the National Abortion Federation’s Clinical Policies Committee.
        Contraception. 2019; 99: 265-266https://doi.org/10.1016/j.contraception.2019.02.008
        • Horvath S.
        • Tsao P.
        • Huang Z.Y.
        • Zhao L.
        • Du Y.
        • Sammel M.D.
        • et al.
        The concentration of fetal red blood cells in first-trimester pregnant women undergoing uterine aspiration is below the calculated threshold for Rh sensitization.
        Contraception. 2020; 102: 1-6https://doi.org/10.1016/j.contraception.2020.02.011
        • Horvath S.
        • Goyal V.
        • Traxler S.
        • Prager S.
        Society of Family Planning committee consensus on Rh testing in early pregnancy.
        Contraception. 2022; 114: 1-5https://doi.org/10.1016/j.contraception.2022.07.002
        • Livshits A.
        • Machtinger R.
        • David L.B.
        • Spira M.
        • Moshe-Zahav A.
        • Seidman D.S.
        Ibuprofen and paracetamol for pain relief during medical abortion: a double-blind randomized controlled study.
        Fertil Steril. 2009; 91: 1877-1880https://doi.org/10.1016/j.fertnstert.2008.01.084
        • Goldman A.R.
        • Porsch L.
        • Hintermeister A.
        • Dragoman M.
        Transcutaneous electrical nerve stimulation to reduce pain with medication abortion: a randomized controlled trial.
        Obstet Gynecol. 2021; 137: 100-107https://doi.org/10.1097/AOG.0000000000004208
        • Dragoman M.V.
        • Grossman D.
        • Nguyen M.H.
        • Habib N.
        • Kapp N.
        • Tamang A.
        • et al.
        Two prophylactic pain management regimens for medical abortion ≤63 days’ gestation with mifepristone and misoprostol: a multicenter, randomized, placebo-controlled trial.
        Contraception. 2021; 103: 163-170https://doi.org/10.1016/j.contraception.2020.12.004
        • Jain J.K.
        • Harwood B.
        • Meckstroth K.R.
        • Mishell D.R.
        Early pregnancy termination with vaginal misoprostol combined with loperamide and acetaminophen prophylaxis.
        Contraception. 2001; 63: 217-221
        • Auffret M.
        • Bernard-Phalippon N.
        • Dekemp J.
        • Carlier P.
        • Gervoise Boyer M.
        • Vial T.
        • et al.
        Misoprostol exposure during the first trimester of pregnancy: Is the malformation risk varying depending on the indication.
        Eur J Obstet Gynecol Reprod Biol. 2016; 207: 188-192https://doi.org/10.1016/j.ejogrb.2016.11.007
        • Vauzelle C.
        • Beghin D.
        • Cournot M.-P.
        • Elefant E.
        Birth defects after exposure to misoprostol in the first trimester of pregnancy: prospective follow-up study.
        Reprod Toxicol. 2013; 36: 98-103https://doi.org/10.1016/j.reprotox.2012.11.009